Trava Health review: the price changes with the prescription

Trava Health sells online access to compounded semaglutide and tirzepatide with monthly and quarterly purchasing options. Its lowest advertised figure does not describe a flat price at every prescribed strength. For a continuing-cost comparison, the important question is what the specific prescription will cost now and what could change at renewal.

We checked Trava’s product displays, expanded public FAQs, provider page and terms on October 15, 2026. This review records published information and visible price selections, not an intake, purchase, pharmacy inspection or patient-outcome test. No AI confidence percentage or numerical quality score is assigned.

The public displays confirm that price varies

The pricing page explicitly says the medication and prescribed strength determine price. It describes a monthly plan supplying one month at a time and a quarterly plan supplying three months, with savings advertised up to 33%. The prominent “as low as $89” message is therefore not a verified ongoing price for every plan.

On the semaglutide page, selecting the lowest displayed strength showed $117.96 monthly; selecting the highest displayed strength showed $187.96. The tirzepatide page showed $178.98 monthly at its lowest selection and $319.98 at its highest. These were public display checks, not quotes for a particular patient or evidence that a clinician should choose any of those strengths.

The product pages also display quarterly savings amounts that change with the selection. We did not complete checkout to verify a full quarterly invoice, taxes or financing terms. Obtain the actual package total and renewal amount rather than treating the savings label or a monthly equivalent as a cancel-any-month payment schedule.

The pricing page lists the doctor consultation, ongoing support and next-day shipping without added fees. Its FAQ says there is no membership program. Those statements do not remove the automatically renewing product subscriptions described in the contract, and they do not establish coverage for every outside test or other service.

Approval determines when the payment hold becomes a charge

The expanded FAQ says the initial evaluation is free and that the full amount is held on the payment card while the doctor evaluates the request. It says the payment is processed only if approved and the hold is released if the applicant is not approved. The pricing FAQ similarly says a charge occurs after a prescription is written.

An authorization hold can affect available funds even before a completed charge. Ask about the hold amount and release timing if that matters to your budget. The public description is not an independently tested refund or banking timeline, and completing the request does not secure a prescription.

Cancel before renewal processing, not before delivery

The June 1, 2026 terms require cancellation at least 48 hours before the subscription’s renewal processing date. They describe cancellation through the service, the online account or the support contacts listed there, with effect at the end of the current subscription period. The simpler FAQ instruction to change portal preferences should be read alongside that deadline.

The terms distinguish stopping the subscription from canceling an individual pharmacy order. Once the order has been transmitted to and processed by the pharmacy, it cannot be canceled, changed or refunded under that policy. There are no refunds for partially used subscription periods; discretionary review of a concern is not a guaranteed refund.

A paused subscription can resume charging automatically when the pause ends. Ask for the next processing date and written confirmation of the action taken. Shipment is not the only relevant cutoff, and a remaining supply of medicine does not itself pause billing.

The pharmacy and medical-practice disclosures do not match

Trava’s expanded FAQ names Optimal Balanced Pharmacy and Vials RX. Its terms instead list TruePill, Curexa, Apostrophe Pharmacy and XeCare as pharmacies available through the service. The provider page describes partnerships with Beluga Health and Bask Health, while the terms name several You Health medical groups. These are inconsistent public lists, not confirmation that every named entity will participate in an order.

The terms identify Trava Health, Inc. as the platform business. Before proceeding, obtain the actual prescribing practice and dispensing pharmacy for your state and preparation, then check the relevant licensing information. The FAQ claims all-state shipping, but this review did not independently audit each state or product’s availability.

Testing language does not establish drug approval

The FAQ attributes third-party testing to Eagle Analytics and uses FDA-approval language for the laboratory. We did not independently verify that laboratory description or inspect a batch-specific report. A testing claim does not establish FDA approval, clinical equivalence or the outcomes of the dispensed compounded drug.

FDA explains that compounded GLP-1 drugs are not FDA-approved and are not evaluated before marketing for safety, effectiveness or quality. Our dual-action explainer also distinguishes a description of receptor targets from evidence about a specific preparation. Neither an ingredient name nor the number of biological targets supplies a quality score.

Finally, separate shipping from care response. The pricing page advertises next-day shipping, while the FAQ describes standard delivery in two to three business days and possible holiday delays. These are company logistics claims, not measured clinician-response times or a guaranteed checkout-to-arrival interval. For a different billing pattern, our Brello review examines packages that renew every eleven or twenty-two weeks.